Rishena Medical (瑞神安)

Rishena operates in medical devices, with a focus on active implants and neuromodulation. Its described portfolio reaches across spinal cord stimulation (SCS), vagus nerve stimulation (VNS), deep-brain or closed-loop stimulation, and stereoelectroencephalography (SEEG) electrodes. It also lists a non-implantable auricular VNS device and, in company materials, an implantable drug delivery system. This range suggests a broader product mix than a company focused on a single stimulation modality, combining therapeutic implants with devices used in neurosurgical diagnosis. Its stated differentiators are the breadth of its neural-device portfolio, reported experience in active implants, and claimed manufacturing capabilities, including a 100,000-class cleanroom. Company materials also report more than 100 patents and core technologies and multiple Class II and Class III devices brought to market in China, but those claims are not accompanied here by dated product-level evidence. Rishena is privately held, and its only listed financing is an undisclosed 2015 venture round.

Rishena's available history points to a specialist medical-device business founded in 2012, with a listed venture round dated Jan 1, 2015. The company is associated with an employee range of 51–100, but this is a range rather than a dated headcount series. Its product lineup indicates development across several related applications: implantable spinal cord and vagus nerve stimulation, auricular VNS, intracranial electrodes for SEEG procedures, and a closed-loop brain stimulator described as under clinical trial. Company materials cite more than 100 patents and core technologies, a 100,000-class cleanroom, and multiple Class II and Class III products brought to market in China; without dates or independent product-level detail, these are best treated as reported capabilities rather than evidence of a particular growth inflection. Overall, the available profile supports a continuing medical-device operation, but offers limited dated evidence with which to assess its trajectory since 2015.